Biotechnology
Neurological Biomarkers Market

Neurological Biomarkers Market Size, Share, Trends, Growth, and Regional Forecasts 2025 - 2032

Neurological Biomarkers Market by Biomarkers Type ((Proteomic Biomarkers, Genomic Biomarkers, Neuroimaging Biomarkers, Metabolomics Biomarkers), Sample (Blood, Plasma, Cerebrospinal Fluid, Others), Indication, End-user and Regional Analysis for 2025 - 2032

ID: PMRREP16303

April 2025

170 Pages

Author : Pravin Rewale

Healthcare

Neurological Biomarkers Market Share and Trends Analysis

According to the Persistence Market Research, the global neurological biomarkers market value is estimated to grow from US$ 9.5 Billion in 2025 to US$ 19.1 Billion by 2032. The market is projected to record a CAGR of 10.4% by 2032. The rising prevalence of neurological disorders and advances in molecular biology, such as gene sequencing and proteomics, alongside neuroimaging techniques are expanding the application of biomarkers in diagnostics and treatment. According to the World Health Organization, the global burden of neurological diseases is expected to increase substantially, further driving demand for early diagnostic tools.

Key Industry Highlights:

Rising neurological disorders and advances in molecular diagnostics accelerates the global demand for neurology biomarkers.
Proteomic biomarkers dominate due to their clinical relevance in reflecting disease phenotypes and disease progression.
North America accounts for the large share driven by robust investments in neuroscience R&D and advanced diagnostic technologies.
Europe is witnessing rapid growth with an increased demand for early diagnostic biomarkers for neurodegenerative diseases.
Advancements in genomics and proteomics accelerate biomarker discovery, enabling earlier diagnosis and personalized treatment strategies.

Global Market Attribute	Key Insights
Neurological Biomarkers Market Size (2025E)	US$ 9.5 Bn
Market Value Forecast (2032F)	US$ 19.1 Bn
Projected Growth (CAGR 2025 to 2032)	10.4%
Historical Market Growth (CAGR 2019 to 2024)	8.8%

Market Dynamics

Driver - Advancements in Genomics and Proteomics Facilitating Neurological Biomarker Discovery

Advancements in genomics and proteomics have notably accelerated the discovery of neurological biomarkers, improving the diagnosis and treatment of neurological disorders. Genomics and proteomics identify gene mutations and protein biomarkers aiding early diagnosis and personalized treatments, improving outcomes in neurodegenerative diseases. Advancements in next-generation sequencing (NGS) and mass spectrometry are further accelerating genomics and proteomics discoveries by identifying genetic variants such as APOE, APP, PSEN1, and PSEN2 linked to Alzheimer’s risk. Growing usage in neurological disease research is driving the global market.

In January 2025, the UK Biobank in collaboration with 14 pharmaceutical companies launched a 2025 proteomics initiative that analyzes blood samples from 500,000 participants to identify up to 5,400 proteins. This project uses AI to enhance disease prediction, treatment targeting, and overall understanding of neurological conditions.

Restraints - Challenges in Clinical Validation Slowing Neurological Biomarker Advancements

Clinical trials for validating biomarkers are time-consuming and costly, often needing large patient cohorts to ensure statistical significance. This is particularly challenging in neurological diseases, where patient recruitment can be difficult, and disease progression may vary widely. As a result, many biomarkers fail to meet the rigorous standards by regulatory bodies, such as the FDA or EMA. Additionally, there is a lack of standardized protocols for biomarker testing in clinical settings, which leads to inconsistencies in results. The variability of biomarkers in the population further complicates the establishment of universally accepted standards. Despite significant progress in the discovery of neurological biomarkers challenges clinical validation, thus slowing their widespread adoption.

Opportunity - Integration of AI and Machine Learning in Biomarker Research Fosters Faster Discoveries and Applications

AI and ML presents a major opportunity for researchers and biotech firms by enabling rapid analysis of complex genomic, proteomic, and imaging data. These technologies help identify novel neurological biomarkers, predict disease progression, and tailor treatments. Their ability to process large datasets efficiently accelerates discovery, supports personalized medicine, and shortens time-to-market for diagnostics and therapies. In December 2023, Quibim, a pioneer in imaging biomarkers for Precision Medicine, launched QP-Brain® after receiving FDA 510(k) clearance, a CE mark for the EU, and a UKCA mark for the UK, enabling its clinical use.

Get Your CustomizationGet Your Customization

Category-wise Analysis

Biomarker Type Insights

Proteomics biomarkers accounted for 35.4% share in 2024, Proteomic biomarkers are preferred over genomic or metabolomics counterparts due to their higher clinical relevance in reflecting disease phenotype. Unlike genomic biomarkers, which indicate static risk factors, proteomic markers capture dynamic biological responses such as protein misfolding or aggregation central to neurological disorders. Their closer correlation with pathophysiological changes enables more accurate disease staging, early intervention, and real-time treatment monitoring. This translational advantage makes proteomics a more effective tool for guiding therapeutic decisions and developing targeted neurology drugs, driving their prioritization in biomarker research and clinical pipelines.

Indication Insights

Alzheimer's disease (AD) is projected to account for over 45% value share within the global market in 2025. High prevalence of Alzheimer is creating significant demand for diagnostic tools for early diagnosis and effective treatment. According to Alzheimer's Association 2025, one in nine people aged 65 and above suffer from Alzheimer's.

Introduction of blood-based biomarker testing and imaging techniques has refined the diagnosis of AD and guided treatment decisions, especially as disease-modifying therapeutics become more prevalent. Biomarkers such as tau proteins and amyloid-beta are crucial for identifying AD in its early stages, enabling the initiation of AD-targeted therapies.

In contrast, other neurological conditions like multiple sclerosis (MS), Parkinson's disease (PD), and Autism spectrum disorder (ASD) still have fewer well-established biomarkers, limiting their market growth relative to Alzheimer's. This disparity in biomarker development further solidifies AD’s dominant position within the global market.

neurological biomarkers market insights and key trends

Regional Insights and Trends

North America Neurological Biomarkers Market Trends

North America accounted for 50.3% of the global market in 2024, with the U.S. emerging as a key player due to the rising prevalence of neurodegenerative diseases such as Alzheimer’s and Parkinson. According to Alzheimer Association, around 6.9 million American populations were affected by Alzheimer’s in 2024, a number projected to rise to 13.8 million by 2060, significantly increasing demand for early diagnostic tools.

Strong emphasis on advancing biomarker research, active research programs and substantial R&D funding are significantly propelling the North American market. The region’s commitment to developing novel biomarkers drive advancements in the early diagnosis and personalized treatment approaches for neurological disorders.

In January 2024, the U.S. National Institutes of Health (NIH) launched a major initiative to refine NFL assay performance, aimed at advancing early Alzheimer’s detection. This reflects a growing investment in biomarker innovation to support timely intervention and disease management.

The growing use of biomarkers in clinical trials and FDA’s Biomarker Qualification Program is accelerating drug development by accepting biomarkers as surrogate endpoints accelerating the approval process for new neurological treatments. The incorporation of artificial intelligence (AI) into biomarker analysis is enhancing diagnostic accuracy, further driving the U.S. neurological biomarker market. Companies such as C2N Diagnostics have pioneered AI-driven blood tests, such as the PrecivityAD2 test (UK MHRA medical device certification in February 2025), which measures amyloid-beta levels to aid in Alzheimer’s disease diagnosis.

Europe Neurological Biomarkers Market Trends

In 2024, Europe held a 24.6% share. Rise in research funding and demand for early diagnosis of conditions such as Alzheimer’s, Parkinson’s, and multiple sclerosis. Advanced blood biomarkers such as p-Tau217 and p-Tau181 is developed to detect these diseases at earlier stages. European governments and private institutions are heavily investing in neuroscience, resulting in specialized research centers and cross-border collaborations.

The UK government allocated an additional US$ 2.5 million in March 2025 for the READ-OUT trial, that focuses on blood biomarkers for early dementia detection. This reflects a wider regional push to enhance diagnostic accuracy and improve patient outcomes through early intervention.

Asia Pacific Neurological Biomarkers Market Trends

Asia Pacific accounted for 13.2% of the global market in 2024. Asia Pacific's growing disease burden is boosting biomarker innovation. The region faces increasing cases of stroke, dementia, and Parkinson’s disease, further fueling demand for early diagnostics.

India neurology biomarker market is witnessing rapid growth, owed to increasing incidence of neurological conditions alongside government programs such as NPCDCS (National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke) that promote advanced diagnostic technologies.

China’s “Healthy China 2030” initiative focuses on early detection and healthcare strengthening. Alzheimer’s Disease International projects China to have over 20 million dementia cases by 2050. These trends highlight the need for scalable diagnostic infrastructure. With advancing technology and a supportive research environment, Asia Pacific is becoming a key player in neurological biomarker innovation.

Request Free sampleRequest Free sample

Competitive Landscape

The global neurological biomarkers market is highly fragmented, with key players focusing on innovation and product development through strategic partnerships. Advancements in biomarker technologies and the growing demand for early disease detection is fueling market expansion and enhancing competitive positioning.

Key Developments:

In March 2025, A recent study by CSL, Australia-based, validated Brainomix's imaging biomarkers as reliable predictors of clinical outcomes in stroke patients. The findings demonstrated improved diagnostic accuracy and treatment decisions, supporting the technology’s clinical value in stroke care.
In December 2024, ESYA Labs partnered with Alamar Biosciences to enhance biomarker detection and diagnostics for neurological diseases, combining their expertise in lysosomal biology with Alamar's NULISA platform and ARGO HT System.
In July 2024, Biogen Inc., Beckman Coulter, and Fujirebio announced a collaboration to identify and develop blood-based tau biomarkers, aiming to advance and commercialize tests for Alzheimer’s disease and support future therapies targeting tau pathology.

Companies Covered in Neurological Biomarkers Market

Quanterix
Amoneta Diagnostics
Bio-Rad Laboratories, Inc
Eli Lilly and Company
IXICO plc
Biognosys
Revvity
Beckman Coulter, Inc.
PreOmics GmbH
ADx NeuroSciences NV (A Fujirebio Company)
Fujirebio
Brainomix
Merck KGaA
Bio-Techne
Assay Genie
SomaLogic Operating Co., Inc.
Siemens Healthineers
Abbott Laboratories
Roche Diagnostics
GE HealthCare
Imaging Endpoints

Frequently Asked Questions

The global market is projected to value at US$ 9.5 Bn in 2025.

The global market is driven by rising neurodegenerative disease prevalence, and rapid adoption of advanced diagnostic and biomarker technologies.

The global market is poised to witness a CAGR of 10.4% from 2025 to 2032.

Emerging non-invasive biomarkers and increasing applications in personalized medicine and early neurological disease detection.

The key players in the neurological biomarkers market include Quanterix, Amoneta Diagnostics, Bio-Rad Laboratories Inc. Fujirebio, Merck KGaA, and others.

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

Global Market Attribute	Key Insights
Neurological Biomarkers Market Size (2025E)	US$ 9.5 Bn
Market Value Forecast (2032F)	US$ 19.1 Bn
Projected Growth (CAGR 2025 to 2032)	10.4%
Historical Market Growth (CAGR 2019 to 2024)	8.8%

Executive Summary
1. Global Neurological Biomarkers Market Snapshot, 2025 and 2032
2. Market Opportunity Assessment, 2025 - 2032, US$ Mn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Industry Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Key Trends
3. Macro-Economic Factors
  1. Global Sectorial Outlook
  2. Global GDP Growth Outlook
4. COVID-19 Impact Analysis
5. Forecast Factors - Relevance and Impact
Value Added Insights
1. Product Adoption Analysis
2. Regulatory Landscape
3. Value Chain Analysis
4. Key Deals and Mergers
5. PESTLE Analysis
6. Porter’s Five Force Analysis
Global Neurological Biomarkers Market Outlook:
1. Key Highlights
  1. Market Size (US$ Mn) and Y-o-Y Growth
  2. Absolute $ Opportunity
2. Market Size (US$ Mn) Analysis and Forecast
  1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
3. Global Neurological Biomarkers Market Outlook: Biomarkers
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Biomarker, 2019-2024
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    1. Proteomic Biomarkers
    2. Genomic Biomarkers
    3. Neuroimaging Biomarkers
    4. Metabolomics Biomarkers
  4. Market Attractiveness Analysis: Biomarkers
4. Global Neurological Biomarkers Market Outlook: Sample
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Sample, 2019-2024
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    1. Blood
    2. Plasma
    3. Cerebrospinal Fluid
    4. Others
  4. Market Attractiveness Analysis: Sample
5. Global Neurological Biomarkers Market Outlook: Indication
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019-2024
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    1. Alzheimer's Disease (AD)
    2. Multiple Sclerosis (MS)
    3. Parkinson's Disease (PD)
    4. Autism Spectrum Disorder (ASD)
    5. Others
  4. Market Attractiveness Analysis: Indication
6. Global Neurological Biomarkers Market Outlook: End-user
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By End-user, 2019-2024
  3. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
    1. Hospital Labs
    2. Diagnostic Centers
    3. Academic & Research Institutes
    4. Biopharma Companies
    5. Proteomic Laboratory
    6. Others
  4. Market Attractiveness Analysis: End-user
Global Neurological Biomarkers Market Outlook: Region
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  1. North America
  2. Europe
  3. East Asia
  4. South Asia & Oceania
  5. Latin America
  6. Middle East & Africa
  7. Market Attractiveness Analysis: Region
North America Neurological Biomarkers Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  1. By Country
  2. By Biomarker
  3. By Sample
  4. By Indication
  5. By End-user
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  1. U.S.
  2. Canada
4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  1. Proteomic Biomarkers
  2. Genomic Biomarkers
  3. Neuroimaging Biomarkers
  4. Metabolomics Biomarkers
5. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  1. Blood
  2. Plasma
  3. Cerebrospinal Fluid
  4. Others
6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  1. Alzheimer's Disease (AD)
  2. Multiple Sclerosis (MS)
  3. Parkinson's Disease (PD)
  4. Autism Spectrum Disorder (ASD)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  1. Hospital Labs
  2. Diagnostic Centers
  3. Academic & Research Institutes
  4. Biopharma Companies
  5. Proteomic Laboratory
  6. Others
8. Market Attractiveness Analysis
Europe Neurological Biomarkers Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  1. By Country
  2. By Biomarker
  3. By Sample
  4. By Indication
  5. By End-user
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  1. Germany
  2. France
  3. U.K.
  4. Italy
  5. Spain
  6. Russia
  7. Türkiye
  8. Rest of Europe
4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  1. Proteomic Biomarkers
  2. Genomic Biomarkers
  3. Neuroimaging Biomarkers
  4. Metabolomics Biomarkers
5. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  1. Blood
  2. Plasma
  3. Cerebrospinal Fluid
  4. Others
6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  1. Alzheimer's Disease (AD)
  2. Multiple Sclerosis (MS)
  3. Parkinson's Disease (PD)
  4. Autism Spectrum Disorder (ASD)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  1. Hospital Labs
  2. Diagnostic Centers
  3. Academic & Research Institutes
  4. Biopharma Companies
  5. Proteomic Laboratory
  6. Others
8. Market Attractiveness Analysis
East Asia Neurological Biomarkers Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  1. By Country
  2. By Biomarker
  3. By Sample
  4. By Indication
  5. By End-user
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  1. China
  2. Japan
  3. South Korea
4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  1. Proteomic Biomarkers
  2. Genomic Biomarkers
  3. Neuroimaging Biomarkers
  4. Metabolomics Biomarkers
5. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  1. Blood
  2. Plasma
  3. Cerebrospinal Fluid
  4. Others
6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  1. Alzheimer's Disease (AD)
  2. Multiple Sclerosis (MS)
  3. Parkinson's Disease (PD)
  4. Autism Spectrum Disorder (ASD)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  1. Hospital Labs
  2. Diagnostic Centers
  3. Academic & Research Institutes
  4. Biopharma Companies
  5. Proteomic Laboratory
  6. Others
8. Market Attractiveness Analysis
South Asia & Oceania Neurological Biomarkers Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  1. By Country
  2. By Biomarker
  3. By Sample
  4. By Indication
  5. By End-user
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  1. India
  2. Southeast Asia
  3. ANZ
  4. Rest of South Asia & Oceania
4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  1. Proteomic Biomarkers
  2. Genomic Biomarkers
  3. Neuroimaging Biomarkers
  4. Metabolomics Biomarkers
5. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  1. Blood
  2. Plasma
  3. Cerebrospinal Fluid
  4. Others
6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  1. Alzheimer's Disease (AD)
  2. Multiple Sclerosis (MS)
  3. Parkinson's Disease (PD)
  4. Autism Spectrum Disorder (ASD)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  1. Hospital Labs
  2. Diagnostic Centers
  3. Academic & Research Institutes
  4. Biopharma Companies
  5. Proteomic Laboratory
  6. Others
8. Market Attractiveness Analysis
Latin America Neurological Biomarkers Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  1. By Country
  2. By Biomarker
  3. By Sample
  4. By Indication
  5. By End-user
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  1. Brazil
  2. Mexico
  3. Rest of Latin America
4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  1. Proteomic Biomarkers
  2. Genomic Biomarkers
  3. Neuroimaging Biomarkers
  4. Metabolomics Biomarkers
5. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  1. Blood
  2. Plasma
  3. Cerebrospinal Fluid
  4. Others
6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  1. Alzheimer's Disease (AD)
  2. Multiple Sclerosis (MS)
  3. Parkinson's Disease (PD)
  4. Autism Spectrum Disorder (ASD)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  1. Hospital Labs
  2. Diagnostic Centers
  3. Academic & Research Institutes
  4. Biopharma Companies
  5. Proteomic Laboratory
  6. Others
8. Market Attractiveness Analysis
Middle East & Africa Neurological Biomarkers Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  1. By Country
  2. By Biomarker
  3. By Sample
  4. By Indication
  5. By End-user
3. Current Market Size (US$ Mn) and Forecast, By Country, 2025-2032
  1. GCC Countries
  2. Egypt
  3. South Africa
  4. Northern Africa
  5. Rest of Middle East & Africa
4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  1. Proteomic Biomarkers
  2. Genomic Biomarkers
  3. Neuroimaging Biomarkers
  4. Metabolomics Biomarkers
5. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  1. Blood
  2. Plasma
  3. Cerebrospinal Fluid
  4. Others
6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  1. Alzheimer's Disease (AD)
  2. Multiple Sclerosis (MS)
  3. Parkinson's Disease (PD)
  4. Autism Spectrum Disorder (ASD)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
  1. Hospital Labs
  2. Diagnostic Centers
  3. Academic & Research Institutes
  4. Biopharma Companies
  5. Proteomic Laboratory
  6. Others
8. Market Attractiveness Analysis
Competition Landscape
1. Market Share Analysis, 2025
2. Market Structure
  1. Competition Intensity Mapping By Market
  2. Competition Dashboard
3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  1. Quanterix
    1. Overview
    2. Segments and Products
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. Amoneta Diagnostics
  3. Bio-Rad Laboratories, Inc
  4. Eli Lilly and Company
  5. IXICO plc
  6. Biognosys
  7. Revvity
  8. Beckman Coulter, Inc.
  9. PreOmics GmbH
  10. ADx NeuroSciences NV (A Fujirebio Company)
  11. Fujirebio
  12. Brainomix
  13. Merck KGaA
  14. Bio-Techne
  15. Assay Genie
  16. SomaLogic Operating Co., Inc.
  17. Siemens Healthineers
  18. Abbott Laboratories
  19. Roche Diagnostics
  20. GE HealthCare
  21. Imaging Endpoints
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis	Value: US$ Mn/Bn Volume: As applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Biomarkers Type Sample Indication End-user Region
Competitive Analysis	Quanterix Amoneta Diagnostics Bio-Rad Laboratories, Inc Eli Lilly and Company IXICO plc Biognosys Revvity Beckman Coulter, Inc. PreOmics GmbH ADx NeuroSciences NV (A Fujirebio Company) Fujirebio Brainomix Merck KGaA Bio-Techne Assay Genie SomaLogic Operating Co., Inc. Siemens Healthineers Abbott Laboratories Roche Diagnostics GE HealthCare Imaging Endpoints
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis & Technology Roadmap Future Opportunities and Revenue Pockets Industry Market Analysis Tools
Customization and Pricing	Available upon request

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis	Value: US$ Mn/Bn Volume: As applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Biomarkers Type Sample Indication End-user Region
Competitive Analysis	Quanterix Amoneta Diagnostics Bio-Rad Laboratories, Inc Eli Lilly and Company IXICO plc Biognosys Revvity Beckman Coulter, Inc. PreOmics GmbH ADx NeuroSciences NV (A Fujirebio Company) Fujirebio Brainomix Merck KGaA Bio-Techne Assay Genie SomaLogic Operating Co., Inc. Siemens Healthineers Abbott Laboratories Roche Diagnostics GE HealthCare Imaging Endpoints
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis & Technology Roadmap Future Opportunities and Revenue Pockets Industry Market Analysis Tools
Customization and Pricing	Available upon request

Neurological Biomarkers Market Size, Share, Trends, Growth, and Regional Forecasts 2025 - 2032

Neurological Biomarkers Market by Biomarkers Type ((Proteomic Biomarkers, Genomic Biomarkers, Neuroimaging Biomarkers, Metabolomics Biomarkers), Sample (Blood, Plasma, Cerebrospinal Fluid, Others), Indication, End-user and Regional Analysis for 2025 - 2032